Dose regimen for vancomycin not needing serum peak levels?

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 87, Issue 3, 2002, Pages

  Tan, W H ^a   Brown, N ^a   Kelsall, A W ^b   McClure, R J ^a  

^a Rosie Maternity Hospital   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEWBORN; NEWBORN CARE; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; OTOTOXICITY; POSTNATAL CARE; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 0036828661     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/fn.87.3.f214     Document Type: Article

References (23)

1. Isaacs D. Rationing antibiotic use in neonatal units. Arch Dis Child Fetal Neonatal Ed 2000;82: F1 -2.
2. Cantú TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994;18:533-43.
3. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998;20:473-7.
4. Rodvold KA, Everett JA, Pryka RD, et al. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin Pharmacokinet 1997;33:32-51.
5. Leonard M, Koren G, Stevenson DK, et al. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 1989;8:282-6.
6. Naqvi SH, Keenan WJ, Reichley RM, et al. Vancomycin pharmacokinetics in small, seriously ill infants. American Journal of Diseases in Children 1986;140:107-10.
7. James A, Koren G, Milliken J, et al. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987;31:52-4.
8. Reed MD, Kliegman RM, Weiner JS, et al. The clinical pharmacology of vancomycin in seriously ill preterm infants. Pediatr Res 1987;22:360-3.
9. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995;17:319-26.
10. Schaible DH, Rocci ML, Alpert GA, et al. Vancomycin pharmacokinetics in infants: Relationships to indices of maturation. Pediatr Infect Dis J 1986;5:304-8.
11. Jarrett RV, Marinkovich GA, Gayle EL, et al. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J 1993;12:156-7.
12. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 1999;81:F221-7.
13. Silva R, Reis E, Bispo MA, et al. The kinetic profile of vancomycin in neonates. J Pharm Pharmacol 1998;50:1255-60.
14. Vancomycin, In: British National Formulary 42. London: BMJ Publishing Group, 2001:276-7.
15. Vancomycin, In: Neonatal Formulary. 10th Ed. London: BMJ Publishing Group, 1998:228.
16. Miles MV, Li L, Lakkis H, et al. Special considerations for monitoring vancomycin concentrations in pediatric patients. Ther Drug Monit 1997;3:265-70.
17. Bhatt-Mehta V, Schumacher RE, Faix RG, et al. Lack of vancomycin-associated nephrotoxicity in newborn infants: A case-control study. Pediatrics 1999;103:e48.
18. Koren G, James A. Vancomycin dosing in preterm infants: Prospective verification of new recommendations. J Pediatr 1987;110:797-8.
19. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994;344:1748-50.
20. Duffull SB, Begg EJ. Vancomycin toxicity. What is the evidence for dose dependency? Adverse Drug React Toxicol Rev 1994;13:103-14.
21. Fanos V, Dall'Agnola A. Antibiotics in neonatal infections: A review. Drugs 1999;58:405-27.
22. Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26.
23. Shackley F, Roberts P, Heath P, et al. Trough-only monitoring of serum vancomycin concentrations in neonates. J Antimicrob Chemother 1998;41:141-2.